Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting
Background: Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy. Methods: We retrospectively assessed the incidence of AEs of special interest and managem...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/6/296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433012724301824 |
|---|---|
| author | Ibraheem Othman Seyedeh Zahra (Mona) Moossavi Samaneh Bayati Yi Sin Chang Shubrandu Sanjoy Karolina Grzyb Eric Sy Kayla Cropper Sandy Kassir Waleed Sabry |
| author_facet | Ibraheem Othman Seyedeh Zahra (Mona) Moossavi Samaneh Bayati Yi Sin Chang Shubrandu Sanjoy Karolina Grzyb Eric Sy Kayla Cropper Sandy Kassir Waleed Sabry |
| author_sort | Ibraheem Othman |
| collection | DOAJ |
| description | Background: Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy. Methods: We retrospectively assessed the incidence of AEs of special interest and management strategies in all patients treated with ibrutinib for chronic lymphocytic leukemia (CLL) in Saskatchewan, Canada, since 2014. Results: Among 187 patients (median age 75.7 years, 63% male), the median time from ibrutinib treatment initiation to data cutoff was 3.1 years. Approximately two-thirds of patients received ibrutinib for relapsed CLL (33.7% second-line and 32.6% third-line and beyond), with 33.7% receiving it first-line. All patients initiated ibrutinib as monotherapy at 420 mg. AEs of interest were observed in 81.3% of patients, with 42.8% experiencing ≥2 AEs. No grade 5 AEs were reported. Among the 284 first-onset AEs observed in 152 patients, 90.8% were successfully managed, allowing treatment continuation. The median time to successful management ranged from 27.0 days (range: 12.5–73.0) for infections to 84.0 days (range: 55.0–141.0) for hypertension. Both AE and discontinuation rates were comparable or favourable to previous reports. Conclusion: This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice. |
| format | Article |
| id | doaj-art-60f47a3ba87144efa2fe003dcee03569 |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-60f47a3ba87144efa2fe003dcee035692025-08-20T03:27:13ZengMDPI AGCurrent Oncology1198-00521718-77292025-05-0132629610.3390/curroncol32060296Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World SettingIbraheem Othman0Seyedeh Zahra (Mona) Moossavi1Samaneh Bayati2Yi Sin Chang3Shubrandu Sanjoy4Karolina Grzyb5Eric Sy6Kayla Cropper7Sandy Kassir8Waleed Sabry9Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaEpidemiology and Performance Measurement, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, CanadaResearch Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaResearch Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, CanadaCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, CanadaBackground: Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy. Methods: We retrospectively assessed the incidence of AEs of special interest and management strategies in all patients treated with ibrutinib for chronic lymphocytic leukemia (CLL) in Saskatchewan, Canada, since 2014. Results: Among 187 patients (median age 75.7 years, 63% male), the median time from ibrutinib treatment initiation to data cutoff was 3.1 years. Approximately two-thirds of patients received ibrutinib for relapsed CLL (33.7% second-line and 32.6% third-line and beyond), with 33.7% receiving it first-line. All patients initiated ibrutinib as monotherapy at 420 mg. AEs of interest were observed in 81.3% of patients, with 42.8% experiencing ≥2 AEs. No grade 5 AEs were reported. Among the 284 first-onset AEs observed in 152 patients, 90.8% were successfully managed, allowing treatment continuation. The median time to successful management ranged from 27.0 days (range: 12.5–73.0) for infections to 84.0 days (range: 55.0–141.0) for hypertension. Both AE and discontinuation rates were comparable or favourable to previous reports. Conclusion: This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice.https://www.mdpi.com/1718-7729/32/6/296chronic lymphocytic leukemiaibrutinibadverse eventstreatment discontinuation |
| spellingShingle | Ibraheem Othman Seyedeh Zahra (Mona) Moossavi Samaneh Bayati Yi Sin Chang Shubrandu Sanjoy Karolina Grzyb Eric Sy Kayla Cropper Sandy Kassir Waleed Sabry Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting Current Oncology chronic lymphocytic leukemia ibrutinib adverse events treatment discontinuation |
| title | Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting |
| title_full | Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting |
| title_fullStr | Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting |
| title_full_unstemmed | Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting |
| title_short | Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting |
| title_sort | ibrutinib in elderly patients with chronic lymphocytic leukemia adverse event incidence management and outcomes in a canadian real world setting |
| topic | chronic lymphocytic leukemia ibrutinib adverse events treatment discontinuation |
| url | https://www.mdpi.com/1718-7729/32/6/296 |
| work_keys_str_mv | AT ibraheemothman ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT seyedehzahramonamoossavi ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT samanehbayati ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT yisinchang ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT shubrandusanjoy ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT karolinagrzyb ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT ericsy ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT kaylacropper ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT sandykassir ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting AT waleedsabry ibrutinibinelderlypatientswithchroniclymphocyticleukemiaadverseeventincidencemanagementandoutcomesinacanadianrealworldsetting |